دورية أكاديمية

Mobilization of hematopoietic progenitor cells from allogeneic healthy donors using a new biosimilar G-CSF (Zarzio®).

التفاصيل البيبلوغرافية
العنوان: Mobilization of hematopoietic progenitor cells from allogeneic healthy donors using a new biosimilar G-CSF (Zarzio®).
المؤلفون: Antelo, María Luisa, Zabalza, Amaya, Sánchez Antón, María Piva, Zalba, Saioa, Aznar, Mariví, Mansilla, Cristina, Ramírez, Natalia, Olavarría, Eduardo
المصدر: Journal of Clinical Apheresis; Feb2016, Vol. 31 Issue 1, p48-52, 5p
مستخلص: Peripheral blood progenitor cells (PBPCs) have become the major source of hematopoietic progenitor cells for allogeneic transplantation. In February 2008, Zarzio® was approved by the European Medicine Agency for PBPCs mobilization, but this authorization was not based in trials analyzing safety and efficacy for PBPCs mobilization. Since August 2011, Zarzio® has been used at our institution for PBPCs mobilization. In total 36 healthy family donors underwent PBPCs mobilization, 18 with Neupogen® and 18 with Zarzio®. Donor characteristics were equivalent between groups, and no severe adverse effects were registered in the Zarzio® group. The number of CD34 cells collected/Kg recipient body weight was 6.7 × 106 (3.8-11.1) in the Zarzio® group versus 8.4 × 106 (5.6-16.6) in the Neupogen® group ( P = 0.04). We collected the minimal target cell dose (2 × 106/kg) in all donors from each group and no significant differences were found in the collection of the optimal cell dose (5 × 106/kg) between groups, although 3/18 (16.6%) donors that received Zarzio® failed to mobilize the optimal cell dose compared with 0% in the Neupogen® group. A total of 35 patients proceeded to transplantation (17 in the Zarzio® and 18 in the Neupogen® groups, respectively). Platelet and neutrophil median time to engraftment was comparable between the two groups. Our retrospective study supports the conclusion that Zarzio® mobilization of PBPCs in healthy donors is safe but perhaps not as effective as the reference Neupogen. However, more prospective trials are required to definitively asses the safety and efficacy of G-CSF biosimilars for PBPCs mobilization in healthy donors. J. Clin. Apheresis 31:48-52, 2016. © 2015 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Clinical Apheresis is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:07332459
DOI:10.1002/jca.21401